Updated January 27, 2016, at 6:01 p.m.
The Wall Street Journal has more bad news about Theranos, the blood-testing startup that was once a Silicon Valley darling valued at $9 billion. The Journal reported today that laboratory violations at Theranos would put patients in “immediate jeopardy,” and disqualify the company from participating in the Medicare program.
On Monday, federal health inspectors found “serious deficiencies” at a Theranos lab. It’s not clear what those problems are, though the Journal says the issues are “far more severe” than ones detected in an inspection of the same laboratory in 2013. This comes after the Journal reported in October that Theranos was not yet able—as it claimed—to perform a wide range of lab tests on a pinprick-sized sample of blood.
Because Theranos has raised more than $400 million and made headlines for its eye-popping valuation, its stumbles have been a source of schadenfreude in Silicon Valley. But it would be a shame if its struggles obscured the fact that blood tests in general are justifiably hot right now: they can be used to glean remarkable new insights, even about tumors or other problems that show up only in minuscule amounts. That development won’t be derailed even if Theranos falls apart.
(Source: Wall Street Journal)
Here’s how a Twitter engineer says it will break in the coming weeks
One insider says the company’s current staffing isn’t able to sustain the platform.
Technology that lets us “speak” to our dead relatives has arrived. Are we ready?
Digital clones of the people we love could forever change how we grieve.
How to befriend a crow
I watched a bunch of crows on TikTok and now I'm trying to connect with some local birds.
Starlink signals can be reverse-engineered to work like GPS—whether SpaceX likes it or not
Elon said no thanks to using his mega-constellation for navigation. Researchers went ahead anyway.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.